Literature DB >> 15764753

Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis.

Sadik A Khuder1, Nabeel A Herial, Anand B Mutgi, Douglas J Federman.   

Abstract

STUDY
OBJECTIVE: Studies done both in laboratory animals and humans suggest that nonsteroidal antiinflammatory drug (NSAID) use may reduce the risk of developing lung cancer. Many epidemiologic studies exploring this association lacked sufficient power to draw definitive conclusions. We conducted a metaanalysis to examine the effect of NSAID use on the risk of lung cancer.
DESIGN: We searched the literature using MEDLINE, CANCERLIT, related conference abstracts, and bibliographies of selected studies. The estimators of relative risk (RR) and associated variances, adjusted for the greatest number of confounders, were abstracted and included in the metaanalysis. Combined estimators of RR were calculated using either fixed or random-effect models. Metaanalyses were performed on 14 studies (the number of cases ranged from 81 to 2,560) that examined the association between lung cancer and NSAIDs. Further, subgroup analyses were performed on the nine studies that had adjusted for the effects of smoking.
RESULTS: The combined estimate of RR was 0.79 (95% confidence interval [CI], 0.66 to 0.95) when all the studies were included in the analysis, and was 0.68 (95% CI, 0.55 to 0.85) when the analysis was limited to the subgroup of studies adjusted for smoking. The combined estimates for case-control studies and cohort studies within this subgroup were 0.63 (95% CI, 0.47 to 0.86) and 0.78 (95% CI, 0.62 to 0.98), respectively. We also observed that small cell lung cancer was more inversely associated with NSAID use (RR, 0.48; 95% CI, 0.30 to 0.75) than non-small cell lung cancer (RR, 0.66; 95% CI, 0.56 to 0.79).
CONCLUSION: The findings of this study support an inverse association between NSAID use and risk of lung cancer, but do not suggest a causal relationship.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15764753     DOI: 10.1378/chest.127.3.748

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  31 in total

Review 1.  Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward.

Authors:  David G Menter; Richard L Schilsky; Raymond N DuBois
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  Use of glucosamine and chondroitin and lung cancer risk in the VITamins And Lifestyle (VITAL) cohort.

Authors:  Theodore M Brasky; Johanna W Lampe; Christopher G Slatore; Emily White
Journal:  Cancer Causes Control       Date:  2011-06-25       Impact factor: 2.506

3.  Aspirin and NSAID use and lung cancer risk: a pooled analysis in the International Lung Cancer Consortium (ILCCO).

Authors:  Valerie A McCormack; Rayjean J Hung; Darren R Brenner; Heike Bickeböller; Albert Rosenberger; Joshua E Muscat; Philip Lazarus; Anne Tjønneland; Søren Friis; David C Christiani; Eun-Mi Chun; Loic Le Marchand; Gad Rennert; Hedy S Rennert; Angeline S Andrew; Irene Orlow; Bernard Park; Paolo Boffetta; Eric J Duell
Journal:  Cancer Causes Control       Date:  2011-10-11       Impact factor: 2.506

4.  Non-steroidal anti-inflammatory drugs and cancer incidence by sex in the VITamins And Lifestyle (VITAL) cohort.

Authors:  Theodore M Brasky; John D Potter; Alan R Kristal; Ruth E Patterson; Ulrike Peters; Maryam M Asgari; Mark D Thornquist; Emily White
Journal:  Cancer Causes Control       Date:  2012-01-03       Impact factor: 2.506

5.  Non-steroidal anti-inflammatory drugs and small cell lung cancer risk in the VITAL study.

Authors:  Theodore M Brasky; Christina S Baik; Christopher G Slatore; John D Potter; Emily White
Journal:  Lung Cancer       Date:  2012-05-17       Impact factor: 5.705

6.  Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer.

Authors:  Binglan Zhang; Xuelei Ma; Zhimian Li; Xiang Gao; Fengtian Wang; Lei Liu; Guobo Shen; Yaxiong Sang; Minmin Li; Yuli Li; Jingyi Zhao; Yuquan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-06       Impact factor: 4.553

7.  Association of nonsteroidal anti-inflammatory drugs with lung cancer: results from a large cohort study.

Authors:  Christopher G Slatore; David H Au; Alyson J Littman; Jessie A Satia; Emily White
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-17       Impact factor: 4.254

8.  A novel sulindac derivative inhibits lung adenocarcinoma cell growth through suppression of Akt/mTOR signaling and induction of autophagy.

Authors:  Evrim Gurpinar; William E Grizzle; John J Shacka; Burton J Mader; Nan Li; Nicholas A Piazza; Suzanne Russo; Adam B Keeton; Gary A Piazza
Journal:  Mol Cancer Ther       Date:  2013-02-26       Impact factor: 6.261

9.  Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways.

Authors:  K J Schmitz; R Callies; J Wohlschlaeger; R Kimmig; F Otterbach; J Bohr; H-S Lee; A Takeda; K W Schmid; H A Baba
Journal:  J Clin Pathol       Date:  2006-02-23       Impact factor: 3.411

10.  Lung inflammation, injury, and proliferative response after repetitive particulate hexavalent chromium exposure.

Authors:  Laura M Beaver; Erik J Stemmy; Arnold M Schwartz; Jesse M Damsker; Stephanie L Constant; Susan M Ceryak; Steven R Patierno
Journal:  Environ Health Perspect       Date:  2009-08-19       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.